Georgios P.
- Country
- Greece
- Department
- A' Department of Internal Medicine - Diabetes Department
Research Overview
- A Randomized, Placebo‑Controlled Trial of Zenagamtide (NNC0487‑0111) in Obese Patients with HFpEF or HFmrEF to Reduce CV Death and HF Hospitalization
- Evaluation of the Efficacy and Safety of Semaglutide with Reduced-Dose Insulin Glargine Versus Titrated Insulin Glargine in Type 2 Diabetes with Overweight
- Efficacy and Safety of Cagrilintide and Semaglutide in Patients with Type 2 Diabetes, Chronic Kidney Disease, and Overweight or Obesity
Data & Insights
Has run more than one trial at 16 of 326 partner sites.
Specializations
Diabetes Management
The investigator focuses on innovative therapeutic approaches for type 2 diabetes management, particularly exploring treatment optimization strategies for patients with concurrent overweight conditions.
- Combination Therapy Approaches
- Insulin Optimization
- Weight Management in Diabetes
Their research interests center on examining the therapeutic potential of GLP-1 receptor agonists in combination with modified insulin regimens.
Metabolic Health
The investigator specializes in studying metabolic disorders with particular attention to the intersection of diabetes and obesity-related conditions.
- Glycemic Control Optimization
- Metabolic Parameters Assessment
- Treatment Efficacy Evaluation
Their work involves evaluating treatment efficacy through detailed analysis of glycemic control markers.
Clinical Therapeutics
The investigator explores advanced therapeutic strategies in endocrine disorders, focusing on optimizing medication combinations for improved patient outcomes.
- Insulin Dosing Strategies
- Novel Drug Combinations
- Long-term Treatment Outcomes
Their research encompasses the evaluation of injectable therapeutics and their role in comprehensive diabetes care.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.